Mostrar el registro sencillo del documento

dc.rights.licenseAtribución-SinDerivadas 4.0 Internacional
dc.contributor.advisorQuevedo Buitrago, William Giovanni
dc.contributor.advisorChaves Silva, Diana Carolina
dc.contributor.advisorGónima Valero, Edmundo
dc.contributor.authorRobayo González, Claudia Ximena
dc.date.accessioned2020-02-07T12:57:05Z
dc.date.available2020-02-07T12:57:05Z
dc.date.issued2020-02-06
dc.date.issued2020-02-06
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/75555
dc.description.abstractEntre los medicamentos utilizados para el manejo del dolor se encuentran los analgésicos derivados de los opioides; los cuales representan parte del problema en la epidemia de adicción en Estados Unidos. La información en Colombia es escasa, no hay claridad en de los diagnósticos de dolor, la cantidad de analgésicos formulados, el tiempo de uso, y la relación con el diagnostico de trastorno por consumo de opiáceos. Objetivos: evaluar el trastorno por consumo de opiáceos en pacientes con dolor crónico no oncológico y los factores relacionados. Metodología: Se evaluaron 76 pacientes según los criterios de inclusión, teniendo en cuenta factores de riesgo de adicción, la cantidad de medicación tomada y los criterios por DSM V de trastorno por consumo de opiáceos. Adicional se toma una muestra de orina para evaluar la presencia del tramadol. Resultados: Se encontró una edad promedio de 53,1 años. El 57,89% eran pacientes de sexo femenino, el 18,42% de los pacientes solo cuentan con educación primaria. Los diagnósticos más frecuentes fueron los relacionados con patologías osteomusculares como el lumbago (18,42%). La Equivalentes Diarios de Morfina (EDM) promedio fue de 9,35, el tiempo de uso mas frecuente fue mayor a 1 año. El 64,4% tienen adecuado control del dolor con el medicamento. La valoración de Opioid Risk Tool (ORT) se aumenta si se tienen en cuenta patologías como Trastorno de estrés postraumático (TEPT) y el trastorno de ansiedad. Se presentó una prevalencia del 23,8% de posible trastorno por consumo de opiáceos. Se presentaron 48,64% inmunoensayos positivos. Conclusiones: La valoración y caracterización de los pacientes con manejo analgésico con tramadol arroja datos que demuestran la presencia de diversos factores de riesgo para la presencia de trastorno por uso.
dc.description.abstractOpioid analgesics is one of the most frequent prescriptions for chronic non-cancer pain. It is the leading cause of the opioid epidemic in the United States. In Colombia the information about it is scarce. The statistics about pain diagnosis, opioid analgesics prescription, long term use, and opioid use disorder is unknown. Aim: To describe the population with tramadol as a prescription for chronic pain. Assess the prevalence of opioid use disorder in patients with chronic non-cancer pain and the related risk factors. Methods: 76 patients with the inclusion criteria were included. A structured survey was apply covering questions about pain, time with the medication, visual analog pain scale, evaluation of risk factors with Opioid Risk Tool, meeting the DSM V criteria, and a urine sample was taken. Results: the simple mean age was 53,1 years. The 57,89% were women; 18,42% of the patients only had primary education. The most frequent diagnosis was low back (18,42%). The mean of Morphine Equivalent Miligram (MEM) was 9,35; most of the patients were on tramadol for longer than a year. The 64,4% had control of the pain with the medication. Opioid Risk Tool (ORT) rates higher with the inclusion of Postraumatic Stress Disorder (PTSD) and anxiety disorder. The presence of opioid use disorder was 23,8% in the sample, and 17,11% in the patients with tramadol for longer than a year. 48,64% of the immunoassays were positive. Conclusions. The characterization of the patients with tramadol shows the presence of various risk factors, an overdiagnosis of opioid use disorder with the DSM V criteria and possible use of immunoassays on the follow up of patients.
dc.format.extent129
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rightsDerechos reservados - Universidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/
dc.subject.ddcMedicina y salud
dc.titlePrevalencia de “trastorno por consumo de opiáceos” y presencia tramadol en orina en pacientes en tratamiento de dolor no oncológico en una clínica de dolor. Bogotá. 2019
dc.title.alternativePrevalence of “opioid use disorder” and presence of tramadol in urine of patients on non-cancer pain treatment in a pain clinic. Bogotá 2019
dc.typeReporte
dc.rights.spaAcceso abierto
dc.coverage.sucursalUniversidad Nacional de Colombia - Sede Bogotá
dc.description.additionalMagíster en Toxicología. Línea de Investigación: Comportamiento de las Variables Toxicológicas y de Salud relacionadas con el consumo de sustancias psicoactivas.
dc.type.driverinfo:eu-repo/semantics/other
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.contributor.researchgroupSustancias Psicoactivas
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.references1. Lewis, N. S., Lewin, N. A., Howland, M. A., Hoffman, R. S., Goldfrank, L. R., & Flomenbaum NE. Goldfrank´s Toxicologic Emergencies. NEW YORK: MCGRAW-HILL; 2011. 559–578 p. 2. Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci. 1993;90(12):5391–3. 3. George F. Koob MAA and MLM. Drugs, Addiction, and the Brain. In: Drugs, Addiction, and the Brain [Internet]. Hoboken, NJ, USA: Elsevier; 2014. p. 134–71. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780123869371010011 4. BARCELOUX DG. MEDICAL TOXICOLOGY OF DRUG ABUSE. A JOHN WILEY & SONS, INC., PUBLICATION; 2011. 514–609 p. 5. Salsitz EA. Chronic Pain, Chronic Opioid Addiction: a Complex Nexus. J Med Toxicol [Internet]. 2016 Mar 24;12(1):54–7. Available from: http://link.springer.com/10.1007/s13181-015-0521-9 6. Volkow ND, McLellan AT. Opioid Abuse in Chronic Pain - Misconceptions and Mitigation Strategies. N Engl J Med [Internet]. 2016;374(13):1253–63. Available from: http://www.nejm.org/doi/full/10.1056/NEJMra1507771 7. Peck J, Gill JS, Simopoulos TT, Kaye AD, Viswanath O, Jones MR. A Brief History of the Opioid Epidemic and Strategies for Pain Medicine. Pain Ther [Internet]. 2018;7(1):13–21. Available from: https://doi.org/10.1007/s40122-018-0097-6 8. Porter J. Addiction Rare in Patients treated with narcotics. N Engl J Med. 1976;302(2):123. 9. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain [letter]. Pain [Internet]. 1987;29(2):257–62. Available from: https://ac-els-cdn-com.proxygw.wrlc.org/0304395986900916/1-s2.0-0304395986900916-main.pdf?_tid=4b8c4358-a977-11e7-ad4f-00000aab0f01&acdnat=1507171729_d8c242ce02e55729dd8e0e6e39df2e79 10. Salud OM de la. Alivio del dolor en el cáncer. OMS. 1996. p. 64. 11. Joranson DE, Gilson AM, Dahl JL, Haddox JD. Pain management, controlled Substances, and State Medical Board Policy: A decade of change. J Pain Symptom Manage. 2002;23(2):138–47. 12. Shah A, Hayes CJ, Martin BC. Morbidity and Mortality Weekly Report Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015 [Internet]. Vol. 66. 2017. Available from: http://www.pdmpassist.org/pdf/ 13. Hedegaard H, Warner M, Minino AM. Drug Overdose Deaths in the United States, 1999-2016 [Internet]. NCHS Data Brief. 2017. Available from: https://www.cdc.gov/nchs/govdelivery.htm.%0AFor 14. Asociación Latinoamericana de Cuidados Paliativos. Uso de opioides en el tratamiento del dolor. Primera. Patricia Bonilla. Liliana De Lima. Paola Díaz. Marta Ximena León. Marcela González, editor. Manual para Latinoamérica. Caracas, Venezuela; 2011. 1–112 p. 15. De Lima L. El uso de medicamentos opioides en el alivio del dolor por cáncer en Latinoamérica. Rev Colomb Anestesiol [Internet]. 2006;34(4):253–7. Available from: http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Uso+de+buprenorfina+transd�rmica+en+el+alivio+del+dolor+por+c�ncer#0 16. Organización Panamericana de la Salud. Epidemiología del uso de drogas en América Latina y el Caribe : Un enfoque de salud pública. Organización Panamericana de la Salud. 2009. 1–35 p. 17. Gomez, Alfonso M de J y derecho, Ruiz Gomez F, Mathiasen B. Estudio De Consumo De Sustancias Psicoactivas En Colombia 2013. https://www.unodc.org/documents/colombia/2014/Julio/Estudio_de_Consumo_UNODC.pdf. 2013;9:175. 18. Narváez ÁV, Ruano C, Ávila MP, Latorre S, Manosalva G, Malaver S, et al. Analgésicos en el paciente hospitalizado : Revisión de tema. 2015;44(1):107–27. 19. Buitrago, Claudia Liliana; Rodríguez, Carlos Hernán; Ibarra, Nestor Alfredo; Velásquez, Andrés Felipe; Molina BM. Analgésicos opioides en pacientes hospitalizados. Repert Med y Cirugía. 2014;23(4):276–82. 20. Antolinez Portillo AM, Pérez Sánchez PP, Molina Arteta BM, López Daza D. Consumo de opioides en pacientes hospitalizados en un centro oncológico. Rev Colomb Cancerol [Internet]. 2017 Oct 1 [cited 2018 Jul 17];21(4):194–201. Available from: https://www.sciencedirect.com/science/article/pii/S0123901518300015 21. Onishi E, Kobayashi T, Dexter E, Marino M, Maeno T, Deyo RA. Comparison of Opioid Prescribing Patterns in the United States and Japan: Primary Care Physicians’ Attitudes and Perceptions. J Am Board Fam Med [Internet]. 2017;30(2):248–54. Available from: http://www.jabfm.org/lookup/doi/10.3122/jabfm.2017.02.160299 22. Califf RM, Woodcock J, Ostroff S. A Proactive Response to Prescription Opioid Abuse. N Engl J Med [Internet]. 2016;374(15):1480–5. Available from: http://www.nejm.org/doi/10.1056/NEJMsr1601307 23. Boudreau D, Von Korff M, Rutter CM, Saunders K, Ray GT, Sullivan MD, et al. Trends in De-facto long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166–75. 24. Lipman A, Webster L. The Economic Impact of Opioid Use in the Management of Chronic Nonmalignant Pain. J Manag Care Spec Pharm [Internet]. 2015;21(10):891–9. Available from: http://www.jmcp.org/doi/10.18553/jmcp.2015.21.10.891 25. WHO. Curbing prescription opioid dependency. Bull World Health Organ [Internet]. 2017 May 1;95(5):318–9. Available from: http://www.who.int/bulletin/volumes/95/5/17-020517.pdf 26. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017. Vol. 67, MMWR. Morbidity and Mortality Weekly Report. 2018. 27. Peter Tice. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health [Internet]. (HHS Pulication No. SMA 15-4927, NSDUH Series H-50. 2015. Available from: http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf%5Cnhttp://www.samhsa.gov/data/ 28. Duthey B, Scholten W. Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006. J Pain Symptom Manage. 2014;47(2):283–97. 29. Garcia-Orjuela MG, Alarcon-Franco L, Sanchez-Fernandez JC, Agudelo Y, Zuluaga AF. Dependence to legally prescribed opioid analgesics in a university hospital in Medellin-Colombia: an observational study. BMC Pharmacol Toxicol [Internet]. 2016;17(1):42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27624605%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5022208 30. Peppin JF, Passik SD, Couto JE, Fine PG, Christo PJ, Argoff C, et al. Recommendations for Urine Drug Monitoring as a Component of Opioid Therapy in the Treatment of Chronic Pain. Pain Med [Internet]. 2012;13(7):886–96. Available from: https://academic.oup.com/painmedicine/article-lookup/doi/10.1111/j.1526-4637.2012.01414.x 31. Lara-Solares A, Aguayo Zamora C, Amescua García C, Garcia JBS, Berenguel Cook MDR, Bonilla Sierra P, et al. Latin-American guidelines for opioid use in chronic nononcologic pain. Pain Manag. 2017;7(3):207–15. 32. Ministerio de Sanidad SS e I. Prácticas Seguras para el uso de opioides en pacientes con dolor crónico. Informe 2015. [Internet]. Madrid; 2015. Available from: https://www.seguridaddelpaciente.es/es/proyectos/financiacion-estudios/practica-clinica/opioides-dolor-cronico/ 33. Jiménez JS, Tejedor Varillas A, Carmen Rocío García García, Silvia Gómez García González Sánchez M, Pol. JGVJCHHFVNEN. La atención al paciente con dolor crónico. Documento de consenso. [Internet]. 2015. Available from: https://www.semfyc.es/wp-content/uploads/2016/06/DOCUMENTO-CONSENSO-DOLOR-17-04-A.pdf 34. Degenhardt L, Bruno R, Lintzeris N, Hall W, Nielsen S, Larance B, et al. Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): A cohort study. The Lancet Psychiatry [Internet]. 2015;2(4):314–22. Available from: http://dx.doi.org/10.1016/S2215-0366(15)00005-X 35. Benoliel R, Svensson P, Evers S, Wang S-J, Barke A, Korwisi B, et al. The IASP classification of chronic pain for ICD-11. Pain. 2019;160(1):60–8. 36. Society AP. Pain: current undertanding of assessment, management, and treatments. [Internet]. Available from: http://americanpainsociety.org/uploads/education/npc.pdf 37. Hernández Castro JJ, Moreno Benavides C. El Dolor, Quinto Signo Vital. Med del Dolor [Internet]. 2005;19–34. Available from: http://www.urosario.edu.co/urosario_files/b3/b337b77a-395b-4d96-af63-4f50f7ea3155.pdf 38. Buitrago, Claudia L.; Amaya DM., Pérez MA. ¿Qué saben los pacientes con dolor crónico no oncológico sobre los opioides que les formulan? Repert Med y Cirugía. 2016;5(2):95–100. 39. American Academy of Pain Medicine. Use of Opioids for the Treatment of Chronic Pain [Internet]. 2013 [cited 2017 May 21] p. 1–4. Available from: http://www.asam.org/docs/default-source/public-policy-statements/1opioid-definitions-consensus-2-011.pdf 40. Halbert BT, Davis RB, Wee CC. Disproportionate longer-term opioid use among U.S. adults with mood disorders. Pain [Internet]. 2016 Nov;157(11):2452–7. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006396-201611000-00010 41. LLigoña A, López A, et al. Guía de consenso para el buen uso de analgésicos opioides [Internet]. Socidrogalcohol. 2017. 127–135 p. Available from: http://www.pnsd.msssi.gob.es/profesionales/publicaciones/catalogo/bibliotecaDigital/publicaciones/pdf/2017_GUIA_Buen_uso_opioides_Socidrigalcohol.pdf 42. Covarrubias A, Guevara U, Gutiérrez C, Betancourt JA, Córdova J. Epidemiología del dolor crónico en México. Rev Mex Anestesiol [Internet]. 2010;33(4):207–13. Available from: www.medigraphic.org.mx 43. Pablo J, Carlos J. Revisión sistemática: epidemiología del dolor crónico no oncológico en Chile. Rev El Dolor [Internet]. 2013;59:10–7. Available from: http://www.ached.cl/upfiles/revistas/documentos/53dfbe675a347_original1_59.pdf 44. Aura A:, Guerrero M, María L, Gómez López P. VIII Estudio Nacional de Dolor 2014 PREVALENCIA DEL DOLOR CRONICO EN COLOMBIA Firma encuestadora: Datexco [Internet]. [cited 2019 Jul 6]. Available from: https://dolor.org.co/biblioteca/encuestas/VIII Estudio Prevalencia dolor cronico en colombia publicacion pagina ACED 2014.pdf 45. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Reports [Internet]. 2016;65(1):1–49. Available from: http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm 46. Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in Tramadol: Pharmacology, Metabolism, and Misuse. Anesth Analg. 2017;124(1):44–51. 47. Lopez. JBSGMPG. Latin American Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain (United Kingdom) [Internet]. 2017;21(1):3–19. Available from: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1532-2149%0Ahttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed18b&NEWS=N&AN=613769577 48. Korff M Von, Saunders K, Ray GT, Boudreau D, Campbell C, Merrill J, et al. Defacto Long-term Opioid Therapy for Non-Cancer Pain. Clin J Pain. 2008;24(6):521–7. 49. Bohnert ASB, Logan JE, Ganoczy D, Dowell D. A Detailed Exploration Into the Association of Prescribed Opioid Dosage and Overdose Deaths Among Patients With Chronic Pain. Med Care [Internet]. 2016;54(5):435–41. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005650-201605000-00004 50. Roger Chou, Gilbert J. Fanciullo, Perry G. Fine, 3 Jeremy A. Adler, 4 Jane C. Ballantyne, 5 Pamela Davies, 6 Marilee I. Donovan, 7 David A. Fishbain, 8 Kathy M. Foley, 9 Jeffrey Fudin, 10 Aaron M. Gilson, 11 Alexander Kelter, 12 Alexander Mauskop, 13 Patr 20 and Christine Miaskowski. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J Pain [Internet]. 2012;10(1):886–96. Available from: https://academic.oup.com/painmedicine/article-lookup/doi/10.1111/j.1526-4637.2012.01414.x 51. Guy GP, Zhang K, Bohm MK, Losby J, Lewis B, Young R, et al. Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep [Internet]. 2017;66(26):697–704. Available from: http://www.cdc.gov/mmwr/volumes/66/wr/mm6626a4.htm 52. Jamison RN, Mao J. Opioid Analgesics. Mayo Clin Proc [Internet]. 2015;90(7):957–68. Available from: http://dx.doi.org/10.1016/j.mayocp.2015.04.010 53. Seal KH, Shi Y, Cohen G, Cohen BE, Maguen S, Krebs EE, et al. Association of Mental Health Disorders With Prescription Opioids and High-Risk Opioid Use in US Veterans of Iraq and Afghanistan. Jama-Journal Am Med Assoc. 2012;307(9):940–7. 54. Goodman L GA. Analgésicos Opioides. Manual de Farmacología Y Terapéutica. Mexico: McGraw-Hill; 2010. 492–519 p. 55. Moal GFKM Le. Opioids. In: Neurobilogy of addiction. Primera. Burlington: Elsevier Inc.; 2006. p. 121–71. 56. Cossio MLT, Giesen LF, Araya G, Pérez-Cotapos MLS, Vergara RL, Manca M, et al. Goodman & Gilman. Las bases farmacológicas de la terapéutica [Internet]. Vol. XXXIII, Uma ética para quantos? 2007. 1–2045 p. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15003161%5Cnhttp://cid.oxfordjournals.org/lookup/doi/10.1093/cid/cir991%5Cnhttp://www.scielo.cl/pdf/udecada/v15n26/art06.pdf%5Cnhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84861150233&partnerID=tZOtx3y1 57. Central HM. Guías de manejo del dolor. Gónima E, editor. Bogotá, Colombia.: Hospital Militar Central; 2009. 265 p. 58. Barceloux DG. Medical Toxicology of Drug Abuse [Internet]. Vol. 2, Academic Forensic Pathology. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2012. xii–xii. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780123869371010011 59. McAnally HB. Opioid Dependence [Internet]. Cham: Springer International Publishing; 2018. 1–7 p. Available from: http://link.springer.com/10.1007/978-3-319-47497-7 60. Solhaug V, Molden E. Individual variability in clinical effect and tolerability of opioid analgesics – Importance of drug interactions and pharmacogenetics. Scand J Pain. 2017;17:193–200. 61. Rogério dos Santos Alves; Alex Soares de Souza et all. Drugs and Poisons in Humans [Internet]. Springer. Berlin/Heidelberg: Springer-Verlag; 2005. 1–5 p. Available from: http://link.springer.com/10.1007/3-540-27579-7 62. Saba R, Kaye AD, Urman RD. Pharmacogenomics in Pain Management. Anesthesiol Clin. 2017;35(2):295–304. 63. Zhang F, Tong J, Hu J, Zhang H, Ouyang W, Huang D, et al. COMT Gene Haplotypes Are Closely Associated with Postoperative Fentanyl Dose in Patients. Anesth Analg. 2015;120(4):933–40. 64. Senagore AJ, Champagne BJ, Dosokey E, Brady J, Steele SR, Reynolds HL, et al. Pharmacogenetics-guided analgesics in major abdominal surgery: Further benefits within an enhanced recovery protocol. Am J Surg [Internet]. 2017;213(3):467–72. Available from: http://dx.doi.org/10.1016/j.amjsurg.2016.11.008 65. Owusu Obeng A, Hamadeh I, Smith M. Review of Opioid Pharmacogenetics and Considerations for Pain Management. Pharmacotherapy. 2017;37(9):1105–21. 66. Stamer UM, Musshoff F, Stüber F, Brockmöller J, Steffens M, Tzvetkov M V. Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. Pain. 2016;157(11):2467–75. 67. S. G, A. S. Clinical pharmacology of tramadol. Clin Pharmacokinet [Internet]. 2004;43(13):879–923. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&AN=2004467401 68. Salvador E, Aliaga L. Combinación de opioides. Rev la Soc Esp del Dolor. 2016;23(3):159–63. 69. Hara K, Minami K, Sata T. The effects of tramadol and its metabolite on glycine, γ-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Anesth Analg. 2005;100(5):1400–5. 70. Hernández-Ortiz A. Equianalgesia y rotación opioide en el perioperatorio. Rev Mex Anestesiol [Internet]. 2015;38:172–4. Available from: http://www.medigraphic.com/rma 71. SAMHSA Substance Abuse and Mental Health Services Administration. Clinical Drug Testing in Primary Care. Tech Assist Publ 32. 2012; 72. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27(3):260–7. 73. Pergolizzi J, Pappagallo M, Stauffer J, Gharibo C, Fortner N, De Jesus MN, et al. The Role of Urine Drug Testing for Patients on Opioid Therapy. Pain Pract [Internet]. 2010 Nov;10(6):497–507. Available from: http://doi.wiley.com/10.1111/j.1533-2500.2010.00375.x 74. Knezevic NN, Khan OM, Beiranvand A, Candido KD. Repeated Quantitative Urine Toxicology Analysis May Improve Chronic Pain Patient Compliance with Opioid Therapy. Pain Physician [Internet]. 2017;20(2S):S135–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28226335 75. Magnani B, Kwong T. Urine Drug Testing for Pain Management. Clin Lab Med [Internet]. 2012;32(3):379–90. Available from: http://dx.doi.org/10.1016/j.cll.2012.07.001 76. J.L. S, W.C. B, D.P. A, A. K, A.R. W, B.J. T. Systematic review: Treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med [Internet]. 2010;152(11):712–20. Available from: http://www.annals.org/contents-by-date.2008.shtml%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed9&NEWS=N&AN=2010400231 77. Ceasar R, Chang J, Zamora K, Hurstak E, Kushel M, Miaskowski C, et al. Primary care providers’ experiences with urine toxicology tests to manage prescription opioid misuse and substance use among chronic noncancer pain patients in safety net health care settings. Subst Abus [Internet]. 2016 Jan 2;37(1):154–60. Available from: https://www.tandfonline.com/doi/full/10.1080/08897077.2015.1132293 78. Boston University School of Medicine. SCOPE of Pain : Safe and Competent Opioid Prescribing Education. 2016; Available from: http://media.mycme.com/documents/215/scope_digestfinal_53727.pdf%5Cnhttp://www.mycme.com/scope-of-pain-safe-and-competent-opioid-prescribing-education/activity/2160/?DCMP=ILC-mycme_us_Scopeofpain_HME_031516&spMailingID=13970041&spUserID=MTg1NzQ5NTAzMTQ0S0 79. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J Pain [Internet]. 2009;10(2):113-130.e22. Available from: http://dx.doi.org/10.1016/j.jpain.2008.10.008 80. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE Score: Predicting Outcomes of Opioid Prescribing for Chronic Pain. J Pain. 2006;7(9):671–81. 81. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432–42. 82. Jones, PhD T, Lookatch, MA S, Moore, PhD T. Validation of a new risk assessment tool: The Brief Risk Questionnaire. J Opioid Manag. 2015;11(2):171. 83. Instituto de Evaluación Tecnológica en Salud. Guía de práctica clínica para el tratamiento con opioides del dolor crónico no oncológico en población adulta y pediátrica en Colombia [Internet]. 2019. Available from: http://www.iets.org.co/proyectos-en-curso/Documents/GPC- dolor crónico no oncológico %281%29.pdf 84. Department of Veterans Affairs. VA / DoD CLINICAL PRACTICE GUIDELINE FOR MANAGEMENT OF OPIOID THERAPY FOR CHRONIC PAIN. 2017; 85. Lovejoy TI, Dobscha SK, Turk DC, Weimer MB, Morasco BJ. Correlates of prescription opioid therapy in Veterans with chronic pain and history of substance use disorder. 2016;53(1):97239. 86. Dobscha SK, Morasco BJ, Duckart JP, Macey T, Deyo RA. Correlates of prescription opioid initiation and long-term opioid use in veterans with persistent pain. Clin J Pain. 2013;29(2):102–8. 87. Saunders JB. Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11. Curr Opin Psychiatry. 2017;30(4):227–37. 88. American Psychiatric Association. Guía de consulta de los criterios diagnósticos del DSM-5® [Internet]. Arlington, Virginia: American Psychiatric Publishing; 2013. 1–492 p. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425657 89. López MB, Conde K, Cremonte M. Alcohol use disorders in argentinian girls and women 12 months before delivery: Comparison of DSM-IV, DSM-5, and ICD-10 diagnostic criteria. J Addict Med. 2017;11(2):106–13. 90. Bartoli F, Carrà G, Biagi E, Crocamo C, Dakanalis A, Di Carlo F, et al. Agreement between DSM-IV and DSM-5 criteria for alcohol use disorder among outpatients suffering from depressive and anxiety disorders. Am J Addict. 2017;26(1):53–6. 91. Slade T, Chiu W-T, Glantz M, Kessler RC, Lago L, Sampson N, et al. A Cross-National Examination of Differences in Classification of Lifetime Alcohol Use Disorder Between DSM-IV and DSM-5: Findings from the World Mental Health Survey. Alcohol Clin Exp Res [Internet]. 2016 Aug;40(8):1728–36. Available from: http://doi.wiley.com/10.1111/acer.13134 92. Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, et al. Nonmedical Prescription Opioid Use and <em>DSM-5</em> Nonmedical Prescription Opioid Use Disorder in the United States. J Clin Psychiatry [Internet]. 2016 Jun 22;77(06):772–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27337416%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5555044 93. Wu LT, McNeely J, Subramaniam GA, Brady KT, Sharma G, VanVeldhuisen P, et al. DSM-5 substance use disorders among adult primary care patients: Results from a multisite study. Drug Alcohol Depend [Internet]. 2017;179(July):42–6. Available from: http://dx.doi.org/10.1016/j.drugalcdep.2017.05.048 94. Gallśtegui JS. Convención única de 1961 sobre estupefacientes. Salud Publica Mex. 1967;9(5):771–93. 95. Colombia C de. Ley 43 de 1980 [Internet]. Bogotá, Colombia.; 1981. Available from: ftp://ftp.camara.gov.co/camara/basedoc/ley/1980/ley_0043_1980.html 96. República de Colombia. Ley 30 de 1986 [Internet]. Colombia; 1986 p. 6. Available from: http://www.acnur.org/t3/fileadmin/Documentos/BDL/2008/6460.pdf?view=1 97. Ministerio de la Protección Social. RESOLUCIÓN 002240 DE 2008 [Internet]. Resolución 002240 de 2008 2008. Available from: http://www.alcaldiabogota.gov.co/sisjur/normas/Norma1.jsp?i=31149#0 98. Ministerior de la protección Social. Resolucion 1478 De 2006 [Internet]. 10 Mayo 2006 p. 1–43. Available from: https://www.invima.gov.co/images/pdf/medicamentos/resoluciones/resolucion 001478 de 2006.pdf 99. Fondo Nacional de Estupefacientes. Listado de medicamentos de control especial y medicamentos monopolio del Estado. Vol. 14. Bogotá, Colombia.; 2016. 100. Center N pain. The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain [Internet]. Busse J, editor. Ontario; 2017. 1–105 p. Available from: https://www.cfpc.ca/chronic-non-cancer-pain-management-opioid-resources/ 101. Gutierrez A, Etna V. Guía sobre manejo farmacológico del dolor. Ser Salud Rosarista Doc Investig [Internet]. 2007;1–60. Available from: http://www.urosario.edu.co/urosario_files/fd/fdaaf95a-d1ce-45b4-b62f-c7675b2e5f18.pdf 102. Hospital Militar Central. Caracterización de usuarios 2019 | Hospital Militar Central [Internet]. Paper. 2019 [cited 2019 Oct 5]. Available from: https://www.hospitalmilitar.gov.co/caracterizacion-de-usuarios-del-homic/caracterizacion-de-usuarios-2019 103. Ltd RD. Urine test strips and microscopy. Diário da República. 2010;2001:1–180. 104. Mahajan G. Role of urine drug testing in the current opioid epidemic. Anesth Analg. 2017;125(6):2094–104. 105. De J, Patricio Q, Examen C, Examen N. CONFIRMACION DE OPIACEOS EN ORINA POR GC / MS. 2014;1–2. 106. Pianori D, Gili A, Masanotti G. Changing the smoking habit: Prevalence, knowledge and attitudes among Umbrian hospital healthcare professionals. J Prev Med Hyg. 2017;58(1):E72–8. 107. International Association for the Study of Pain. IASP Terminology - IASP [Internet]. Web. 2019 [cited 2019 Jul 10]. Available from: https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698&navItemNumber=576 108. Center for Behavioral Health Statistics S. RESULTS FROM THE 2015 NATIONAL SURVEY ON DRUG USE AND HEALTH: DETAILED TABLES [Internet]. [cited 2019 Jul 11]. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.pdf 109. Salm-Reifferscheidt L. Tramadol: Africa’s opioid crisis. Lancet (London, England) [Internet]. 2018;391(10134):1982–3. Available from: http://dx.doi.org/10.1016/S0140-6736(18)31073-0 110. Barocas JA, White LF, Wang J, Walley AY, LaRochelle MR, Bernson D, et al. Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011–2015: A Capture–Recapture Analysis. Am J Public Health [Internet]. 2018 Dec;108(12):1675–81. Available from: https://ajph.aphapublications.org/doi/10.2105/AJPH.2018.304673 111. Yilmaz B, Erdem AF. Simultaneous determination of tramadol and its metabolite in human urine by the gas chromatography-Mass spectrometry method. J Chromatogr Sci. 2015;53(7):1037–43. 112. LeResche L, Saunders K, Dublin S, Thielke S, Merrill JO, Shortreed SM, et al. Sex and Age Differences in Global Pain Status Among Patients Using Opioids Long Term for Chronic Noncancer Pain. J Women’s Heal [Internet]. 2015;24(8):629–35. Available from: http://online.liebertpub.com/doi/10.1089/jwh.2015.5222 113. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-Term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety. J Pain Symptom Manage. 2008;35(2):214–28. 114. Badalà F, Nouri-mahdavi K, Raoof DA. Patterns and Correlates of Prescription Opioid Use in OEF/OIF Veterans with Chronic Non-Cancer Pain. Pain Med. 2011;12(10):1502–9. 115. Degenhardt L, Bruno R, Lintzeris N, Hall W, Nielsen S, Larance B, et al. Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): A cohort study. The Lancet Psychiatry [Internet]. 2015;2(4):314–22. Available from: http://dx.doi.org/10.1016/S2215-0366(15)00005-X
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.proposalAnalgésicos Opioides; Trastornos Relacionados con Opioides; Dolor crónico; Tramadol; test urinarios de drogas
dc.subject.proposalOpioid Analgesics; Opioid-Related Disorders; Chronic pain; Tramadol; Urine drug test
dc.type.coarhttp://purl.org/coar/resource_type/c_1843
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2


Archivos en el documento

Thumbnail
Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento

Atribución-SinDerivadas 4.0 InternacionalEsta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.Este documento ha sido depositado por parte de el(los) autor(es) bajo la siguiente constancia de depósito